{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:07:33Z","timestamp":1791209253847,"version":"4.1.0"},"reference-count":73,"publisher":"Informa UK Limited","issue":"19","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,8,9]]},"DOI":"10.1080\/14796694.2025.2527593","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:27:39Z","timestamp":1752136059000},"page":"2429-2438","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Intravesical interferon-\u03b12b gene therapy with nadofaragene firadenovec-vncg: a contemporary review"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0264-6959","authenticated-orcid":false,"given":"Taeweon","family":"Lee","sequence":"first","affiliation":[{"name":"University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Gianchandani","sequence":"additional","affiliation":[{"name":"Imperial College London","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Boorjian","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[{"name":"Carolina Urologic Research Center","place":["Myrtle Beach, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3731-4209","authenticated-orcid":false,"given":"Vikram M.","family":"Narayan","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine","place":["Atlanta, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin P.N.","family":"Dinney","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"European Association of Urology (EAU). European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta T1 and carcinoma in situ). Arnhem (NL): European Association of Urology; 2024. [cited 2024 Dec 1]. Available from: https:\/\/uroweb.org\/guideline\/non-muscle-invasive-bladder-cancer\/"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00307"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.016"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001633"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-159002"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.07.031"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.08.055"},{"key":"e_1_3_5_12_1","unstructured":"US Food and Drug Administration (FDA). Bacillus Calmette-Guerin-unresponsive nonmuscle invasive bladder cancer: developing drugs and biological products for treatment. Bethesda (MD): US Food and Drug Administration; 2022. [cited 2024 Nov 25]. Available from: https:\/\/www.fda.gov\/media\/122019\/download"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.10.030"},{"key":"e_1_3_5_14_1","unstructured":"US Food and Drug Administration (FDA). Adstiladrin\u00ae (nadofaragene firadenovec-vncg). Bethesda (MD): US Food and Drug Administration; 2021. [cited 2024 Nov 25]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/adstiladrin-nadofaragene-firadenovec-vncg"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.08.001"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2005-327"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2203385"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01270"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02443-4"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/181987"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.5.3.697"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.6-1-34"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39547-2"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/1078-1439(95)00039-K"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00455-4"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.06.147"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.10040.x"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2005.11.026"},{"issue":"2","key":"e_1_3_5_30_1","first-page":"1790","article-title":"Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy","volume":"10","author":"Punnen SP","year":"2003","unstructured":"Punnen SP, Chin JL, Jewett MAS. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Can J Urol. 2003;10(2):1790\u20131795.","journal-title":"Can J Urol"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00375-5"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.09.050"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.05.027"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.2527"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1260498"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199904010-00449"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700726"},{"issue":"1","key":"e_1_3_5_38_1","first-page":"210","article-title":"Differential effects of adenovirus-p16 on bladder cancer cell lines can be overcome by the addition of butyrate","volume":"7","author":"Lee CT","year":"2001","unstructured":"Lee CT, Seol JY, Park KH, et al. Differential effects of adenovirus-p16 on bladder cancer cell lines can be overcome by the addition of butyrate. Clin Cancer Res Off J Am Assoc Cancer Res. 2001;7(1):210\u2013214.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-0556-5-10"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-7-148"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90231-E"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62968-9"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700488"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700865"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301348"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.03.030"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.3064"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5300-6"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30540-4"},{"issue":"4","key":"e_1_3_5_50_1","first-page":"1258","article-title":"Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis","volume":"8","author":"Izawa JI","year":"2002","unstructured":"Izawa JI, Sweeney P, Perrotte P, et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res Off J Am Assoc Cancer Res. 2002;8(4):1258\u20131270.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2009.2"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2008.53"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2010.76"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2011.26"},{"issue":"4","key":"e_1_3_5_55_1","first-page":"808","article-title":"Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration","volume":"58","author":"Dinney CP","year":"1998","unstructured":"Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 1998;58(4):808\u2013814.","journal-title":"Cancer Res"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19531"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-010-0494-4"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2520"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1387229"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004020"},{"key":"e_1_3_5_61_1","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. Bethesda (MD): US Department of Health and Human Services; 2017. [cited 2024 Nov 28]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.12.002"},{"key":"e_1_3_5_63_1","unstructured":"US Food and Drug Administration (FDA). FDA approves nogapendekin alfa inbakicept-PMLN for BCG-unresponsive non-muscle invasive bladder cancer. Bethesda (MD): US Food and Drug Administration; 2024. cited 2024 Nov 30]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/nogapendekin-alfa-inbakicept-pmln"},{"key":"e_1_3_5_64_1","unstructured":"US Food and Drug Administration (FDA). Keytruda\u00ae (Pembrolizumab). Bethesda (MD): US Food and Drug Administration; 2023. cited 2024 Nov 30]. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/keytruda-pembrolizumab"},{"key":"e_1_3_5_65_1","unstructured":"US Food and Drug Administration (FDA). FDA grants fast track breakthrough therapy designations to Cretostimogene Grenadenorepvec for NMIBC. Bethesda (MD): US Food and Drug Administration; 2023. [cited 2024 Dec 12]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/da-grants-fast-track-breakthrough-therapy-designations-cretostimogene-grenadenorepvec-nmibc"},{"key":"e_1_3_5_66_1","unstructured":"US Food and Drug Administration (FDA). FDA grants breakthrough therapy designation to TAR-200 for BCG-unresponsive high-risk NMIBC. Bethesda (MD): US Food and Drug Administration; 2023. cited 2024 Dec 12]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-breakthrough-therapy-designation-tar-200-bcg-unresponsive-high-risk-nmibc"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000688"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.12.009"},{"issue":"24","key":"e_1_3_5_69_1","first-page":"00225","article-title":"Minimal residual disease detection with urine-derived DNA is prognostic for recurrence-free survival in bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer treated with nadofaragene firadenovec","volume":"2588","author":"Narayan VM","year":"2024","unstructured":"Narayan VM, Tholomier C, Mokkapati S, et al. Minimal residual disease detection with urine-derived DNA is prognostic for recurrence-free survival in bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer treated with nadofaragene firadenovec. Eur Urol Oncol. 2024;S2588\u20139311(24):00225\u20136.","journal-title":"Eur Urol Oncol"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215297"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.04.014"},{"key":"e_1_3_5_72_1","unstructured":"Ferring Pharmaceuticals. A trial to evaluate intravesical nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy in participants with high-grade BCG unresponsive non-muscle invasive bladder cancer (ABLE-22). Trial registration. Parsippany (NJ): Ferring Pharmaceuticals; 2024. cited 2024 Nov 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03484468"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.06.005"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4632"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS705"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2527593","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2025.2527593","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2527593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:37:25Z","timestamp":1791207445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2527593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":73,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,8,9]]}},"alternative-id":["10.1080\/14796694.2025.2527593"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2527593","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}